Balasa Dinverno & Foltz LLC Has $3.53 Million Holdings in Johnson & Johnson (JNJ)
Balasa Dinverno & Foltz LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,701 shares of the company’s stock after buying an additional 2,427 shares during the quarter. Johnson & Johnson comprises about 0.6% of Balasa Dinverno & Foltz LLC’s investment portfolio, making the stock its 11th biggest position. Balasa Dinverno & Foltz LLC’s holdings in Johnson & Johnson were worth $3,532,000 as of its most recent filing with the SEC.
Other large investors also recently made changes to their positions in the company. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after buying an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new stake in Johnson & Johnson during the 1st quarter valued at $186,000. Taylor Wealth Management Partners grew its holdings in Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after buying an additional 250 shares during the last quarter. Finally, Puplava Financial Services Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $202,000. Hedge funds and other institutional investors own 65.90% of the company’s stock.
A number of equities research analysts have commented on JNJ shares. UBS AG reiterated a “buy” rating and set a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) cut Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their target price for the company from $125.00 to $130.00 in a report on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and set a $145.00 price objective on shares of Johnson & Johnson in a report on Friday, September 1st. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $141.66.
In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.19% of the stock is currently owned by corporate insiders.
Shares of Johnson & Johnson (NYSE JNJ) opened at 142.40 on Friday. The stock’s 50 day moving average price is $133.77 and its 200-day moving average price is $130.75. The stock has a market capitalization of $382.20 billion, a price-to-earnings ratio of 24.77 and a beta of 0.78. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $143.62.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.68 earnings per share. Equities analysts forecast that Johnson & Johnson will post $7.27 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.